Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1868 1
1874 2
1876 1
1877 1
1901 1
1906 3
1908 1
1910 1
1947 1
1953 1
1954 3
1956 3
1957 3
1958 1
1959 1
1960 2
1968 1
1971 3
1972 1
1973 1
1974 4
1975 8
1976 5
1977 7
1978 6
1979 11
1980 13
1981 13
1982 4
1983 3
1984 9
1985 12
1986 12
1987 24
1988 11
1989 19
1990 14
1991 12
1992 14
1993 16
1994 7
1995 21
1996 22
1997 20
1998 12
1999 15
2000 26
2001 24
2002 23
2003 15
2004 16
2005 17
2006 22
2007 25
2008 23
2009 31
2010 21
2011 40
2012 25
2013 20
2014 31
2015 21
2016 35
2017 32
2018 53
2019 46
2020 49
2021 71
2022 59
2023 53
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

1,056 results

Results by year

Filters applied: . Clear all
Page 1
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
Thompson JA, Schneider BJ, Brahmer J, Achufusi A, Armand P, Berkenstock MK, Bhatia S, Budde LE, Chokshi S, Davies M, Elshoury A, Gesthalter Y, Hegde A, Jain M, Kaffenberger BH, Lechner MG, Li T, Marr A, McGettigan S, McPherson J, Medina T, Mohindra NA, Olszanski AJ, Oluwole O, Patel SP, Patil P, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Zaha VG, Lyons M, Dwyer M, Hang L. Thompson JA, et al. J Natl Compr Canc Netw. 2022 Apr;20(4):387-405. doi: 10.6004/jnccn.2022.0020. J Natl Compr Canc Netw. 2022. PMID: 35390769 Review.
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Schneider BJ, et al. Among authors: thompson ja. J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1. J Clin Oncol. 2021. PMID: 34724392
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Brahmer JR, et al. Among authors: thompson ja. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14. J Clin Oncol. 2018. PMID: 29442540 Free PMC article.
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M. Martins F, et al. Among authors: thompson ja. Nat Rev Clin Oncol. 2019 Sep;16(9):563-580. doi: 10.1038/s41571-019-0218-0. Nat Rev Clin Oncol. 2019. PMID: 31092901 Review.
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.
Swetter SM, Thompson JA, Albertini MR, Barker CA, Baumgartner J, Boland G, Chmielowski B, DiMaio D, Durham A, Fields RC, Fleming MD, Galan A, Gastman B, Grossmann K, Guild S, Holder A, Johnson D, Joseph RW, Karakousis G, Kendra K, Lange JR, Lanning R, Margolin K, Olszanski AJ, Ott PA, Ross MI, Salama AK, Sharma R, Skitzki J, Sosman J, Wuthrick E, McMillian NR, Engh AM. Swetter SM, et al. Among authors: thompson ja. J Natl Compr Canc Netw. 2021 Apr 1;19(4):364-376. doi: 10.6004/jnccn.2021.0018. J Natl Compr Canc Netw. 2021. PMID: 33845460
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Kaffenberger BH, Lunning M, McGettigan S, McPherson J, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Pennell N, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wang Y, Weight RM, Johnson-Chilla A, Zuccarino-Catania G, Engh A. Thompson JA, et al. J Natl Compr Canc Netw. 2020 Mar;18(3):230-241. doi: 10.6004/jnccn.2020.0012. J Natl Compr Canc Netw. 2020. PMID: 32135517
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Funchain P, Jaiyesimi I, Mammen JS, Naidoo J, Naing A, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Bollin K, Ghosh M. Santomasso BD, et al. Among authors: thompson ja. J Clin Oncol. 2021 Dec 10;39(35):3978-3992. doi: 10.1200/JCO.21.01992. Epub 2021 Nov 1. J Clin Oncol. 2021. PMID: 34724386
Management of Immunotherapy-Related Toxicities, Version 1.2019.
Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, Budde LE, Costa L, Davies M, Dunnington D, Ernstoff MS, Frigault M, Hoffner B, Hoimes CJ, Lacouture M, Locke F, Lunning M, Mohindra NA, Naidoo J, Olszanski AJ, Oluwole O, Patel SP, Reddy S, Ryder M, Santomasso B, Shofer S, Sosman JA, Wahidi M, Wang Y, Johnson-Chilla A, Scavone JL. Thompson JA, et al. J Natl Compr Canc Netw. 2019 Mar 1;17(3):255-289. doi: 10.6004/jnccn.2019.0013. J Natl Compr Canc Netw. 2019. PMID: 30865922
Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function.
Veatch JR, Lee SM, Shasha C, Singhi N, Szeto JL, Moshiri AS, Kim TS, Smythe K, Kong P, Fitzgibbon M, Jesernig B, Bhatia S, Tykodi SS, Hall ET, Byrd DR, Thompson JA, Pillarisetty VG, Duhen T, McGarry Houghton A, Newell E, Gottardo R, Riddell SR. Veatch JR, et al. Among authors: thompson ja. Cancer Cell. 2022 Apr 11;40(4):393-409.e9. doi: 10.1016/j.ccell.2022.03.006. Cancer Cell. 2022. PMID: 35413271 Free PMC article.
Reply.
Heath Jeffery RC, Lo J, Thompson JA, Lamey TM, McLaren TL, De Roach JN, Ayton LN, Vincent AL, Sharma A, Chen FK. Heath Jeffery RC, et al. Among authors: thompson ja. Ophthalmol Retina. 2023 Dec;7(12):e20-e21. doi: 10.1016/j.oret.2023.07.028. Epub 2023 Aug 28. Ophthalmol Retina. 2023. PMID: 37642631 No abstract available.
1,056 results